|
1
|
Howlader N, Noone AM, Krapcho M, Neyman N,
Aminou R, Waldron W, Altekruse SF, Kosary CL, Ruhl J, Tatalovich Z,
Cho H, Mariotto A, Eisner MP, Lewis DR, Chen HS, Feuer EJ, Cronin
KA and Edwards BK: SEER Cancer Statistics Review, 1975–2008.
National Cancer Institute; Bethesda, MD: 2011
|
|
2
|
Cunningham D, Atkin W, Lenz HJ, Lynch HT,
Minsky B, Nordlinger B and Starling N: Colorectal cancer. Lancet.
375:1030–1047. 2010. View Article : Google Scholar
|
|
3
|
Liao Y, Hu X, Huanq X and He C:
Quantitative analyses of CD133 expression facilitate researches on
tumor stem cells. Biol Pharm Bull. 33:738–742. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Boman BM, Wicha MS, Fields JZ, et al:
Symmetric division of cancer stem cells - a key mechanism in tumor
growth that should be targeted in future therapeutic approaches.
Clin Pharmacol Ther. 81:893–898. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Boman BM, Fields JZ, Cavanaugh KL, Guetter
A and Runquist OA: How dysregulated colonic crypt dynamics cause
stem cell overpopulation and initiate colon cancer. Cancer Res.
68:3304–3313. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Morrison SJ and Kimble J: Asymmetric and
symmetric stem-cell divisions in development and cancer. Nature.
441:1068–1074. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Johnston MD, Edwards CM, Bodmer WF, Maini
PK and Chapman SJ: Mathematical modeling of cell population
dynamics in the colonic crypt and in colorectal cancer. Proc Natl
Acad Sci USA. 104:4008–4013. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Li CY, Li BX, Liang Y, et al: Higher
percentage of CD133+ cells is associated with poor
prognosis in colon carcinoma patients with stage IIIB. J Transl
Med. 7:562009.PubMed/NCBI
|
|
9
|
Huff CA, Matsui WH, Smith DB and Jones RJ:
Strategies to eliminate cancer stem cells: clinical implications.
Eur J Cancer. 42:1293–1297. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Klonisch T, Wiechec E, Hombach-Klonisch S,
Ande SR, Wesselborg S, Schulze-Osthoff K and Los M: Cancer stem
cell markers in common cancers - therapeutic implications. Trends
Mol Med. 14:450–460. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Shmelkov SV, Butler JM, Hooper AT, et al:
CD133 expression is not restricted to stem cells, and both
CD133+ and CD133− metastatic colon cancer
cells initiate tumors. J Clin Invest. 118:2111–2120.
2008.PubMed/NCBI
|
|
12
|
Saigusa S, Tanaka K, Toiyama Y, et al:
Clinical significance of CD133 and hypoxia inducible factor-1α gene
expression in rectal cancer after preoperative chemoradiotherapy.
Clin Oncol (R Coll Radiol). 23:323–332. 2011.PubMed/NCBI
|
|
13
|
Horst D, Kriegl L, Engel J, Kirchner T and
Junq A: Prognostic significance of the cancer stem cell markers
CD133, CD44, and CD166 in colorectal cancer. Cancer Invest.
27:844–850. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kojima M, Ishii G, Atsumi N, Fujii S,
Saito N and Ochiai A: Immunohistochemical detection of CD133
expression in colorectal cancer: a clinicopathological study.
Cancer Sci. 99:1578–1583. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Al-Hajj M, Wicha MS, Benito-Hernandez A,
Morrison SJ and Clarke MF: Prospective identification of
tumorigenic breast cancer cells. Proc Natl Acad Sci USA.
100:3983–3988. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Singh SK, Hawkins C, Clarke ID, et al:
Identification of human brain tumour initiating cells. Nature.
432:396–401. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Boman BM and Wicha MS: Cancer stem cells:
a step toward the cure. J Clin Oncol. 26:2795–2799. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yin AH, Miraglia S, Zanjani ED, et al:
AC133, a novel marker for human hematopoietic stem and progenitor
cells. Blood. 90:5002–5012. 1997.PubMed/NCBI
|
|
19
|
Zeki SS, Graham TA and Wright NA: Stem
cells and their implications for colorectal cancer. Nat Rev
Gastroenterol Hepatol. 8:90–100. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lau CK, Yang ZF and Fan ST: Role of stem
cells in normal liver and cancer. Anticancer Agents Med Chem.
11:522–528. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Monzani E, Facchetti F, Galmozzi E, et al:
Melanoma contains CD133 and ABCG2 positive cells with enhanced
tumourigenic potential. Eur J Cancer. 43:935–946. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Eramo A, Haas TL and De Maria R: Lung
cancer stem cells: tools and targets to fight lung cancer.
Oncogene. 29:4625–4635. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ma S, Chan KW, Hu L, et al: Identification
and characterization of tumorigenic liver cancer stem/progenitor
cells. Gastroenterology. 132:2542–2556. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Maitland NJ and Collins AT: Cancer stem
cells - A therapeutic target? Curr Opin Mol Ther. 12:662–673.
2010.PubMed/NCBI
|
|
25
|
Edling CE and Hallberg B: c-Kit - a
hematopoietic cell essential receptor tyrosine kinase. Int J
Biochem Cell Biol. 39:1995–1998. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Niwa H, Miyazaki J and Smith AG:
Quantitative expression of Oct-3/4 defines differentiation,
dedifferentiation or self-renewal of ES cells. Nat Genet.
24:372–376. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
27
|
Looijenga LH, Stoop H, de Leeuw HP, et al:
POU5F1 (OCT3/4) identifies cells with pluripotent potential in
human germ cell tumors. Cancer Res. 63:2244–2250. 2003.PubMed/NCBI
|
|
28
|
Tsukamoto T, Mizoshita T, Mihara M, et al:
Sox2 expression in human stomach adenocarcinomas with gastric and
gastric-and-intestinal-mixed phenotypes. Histopathology.
46:649–658. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Jia X, Li X, Xu Y, et al: SOX2 promotes
tumorigenesis and increases the anti-apoptotic property of human
prostate cancer cells. J Mol Cell Biol. 3:230–238. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Casas E, Kim J, Bendesky A, Ohno-Machado
L, Wolfe CJ and Yang J: Snail2 is an essential mediator of
Twist1-induced epithelial mesenchymal transition and metastasis.
Cancer Res. 71:245–254. 2011. View Article : Google Scholar
|
|
31
|
Aktas B, Tewes M, Fehm T, Hausch S, Kimmig
R and Kasimir-Bauer S: Stem cell and epithelial-mesenchymal
transition markers are frequently overexpressed in circulating
tumor cells of metastatic breast cancer patients. Breast Cancer
Res. 11:R462009. View
Article : Google Scholar
|
|
32
|
Xi L, Nicastri DG, El-Hefnawy T, Hughes
SJ, Luketich JD and Godfrey TE: Optimal markers for real-time
quantitative reverse transcription PCR detection of circulating
tumor cells from melanoma, breast, colon, esophageal, head and
neck, and lung cancers. Clin Chem. 53:1206–1215. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Iinuma H, Watanabe T, Mimori K, et al:
Clinical significance of circulating tumor cells, including cancer
stem-like cells, in peripheral blood for recurrence and prognosis
in patients with Dukes’ stage B and C colorectal cancer. J Clin
Oncol. 29:1547–1555. 2011.PubMed/NCBI
|
|
34
|
Sher YP, Shih JY, Yanq PC, et al:
Prognosis of non-small cell lung cancer patients by detecting
circulating cancer cells in the peripheral blood with multiple
marker genes. Clin Cancer Res. 11:173–179. 2005.PubMed/NCBI
|
|
35
|
Ong CW, Kim LG, Kong HH, et al: CD133
expression predicts for non-response to chemotherapy in colorectal
cancer. Mod Pathol. 23:450–457. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Saigusa S, Tanaka K, Toiyama Y, et al:
Correlation of CD133, OCT4, and SOX2 in rectal cancer and their
association with distant recurrence after chemoradiotherapy. Ann
Surg Oncol. 16:3488–3498. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Li QQ, Xu JD, Wanq WJ, et al:
Twist1-mediated adriamycin-induced epithelial-mesenchymal
transition relates to multidrug resistance and invasive potential
in breast cancer cells. Clin Cancer Res. 15:2657–2665. 2009.
View Article : Google Scholar
|
|
38
|
Friederichs J, von Weyhern CW, Rosenberg
R, et al: Immunohistochemical detection of receptor tyrosine
kinases c-kit, EGF-R, and PDGF-R in colorectal adenocarcinomas.
Langenbecks Arch Surg. 395:373–379. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Costelloe CM, Chuang HH, Madewell JE and
Ueno NT: Cancer response criteria and bone metastases: RECIST 1.1,
MDA and PERCIST. J Cancer. 28:80–92. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Sobin LH, Gospodarowicz MK and Wittekind
C: TNM Classification of Malignant Tumours. 7th edition.
Wiley-Blackwell; New York: 2009
|
